Event submissions
Leishmaniasis is a neglected tropical disease responsible for the ninth largest disease burden in the world. Excipients are necessary for ensuring the stability and bioavailability of currently available antileishmaniasis drugs. In a recent work, we have evaluated the in vitro activity of 30 commercially available excipients against different Leishmania spp., their cytotoxicity and potential use for inclusion in novel formulations. Ref: Curr Top Med Chem. 2017 Jul 19. https://www.ncbi.nlm.nih.gov/pubmed/28730958